Product Description
[Ac-225]-PSMA-62 is a next-generation PSMA-targeting radioligand comprised of the alpha-emitting radioisotope actinium-225, a chelating moiety, linker, and PSMA-62, a small peptide PSMA inhibitor. In nonclinical models, PSMA-62 showed high PSMA binding affinity, increased cellular internalization, and improved biodistribution, including high tumor retention and rapid renal clearance. (Sourced from: https://www.lillyoncologypipeline.com/molecule/[Ac-225]-PSMA-62/)
Mechanisms of Action: Radioligand Therapy, PSMA
Novel Mechanism: Yes
Modality: Radioligand Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|